Welcome to our dedicated page for Keen Vision Acquisition SEC filings (Ticker: kvacw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Trying to follow KVACW’s fast-moving SPAC disclosures? Between redemption tables, biotech risk factors, and sponsor warrant clauses, Keen Vision Acquisition Corp. filings can easily top 300 pages. Our platform eliminates that complexity so you can focus on the numbers that move the stock.
Stock Titan’s AI reads every document the instant it hits EDGAR, then serves clear answers to questions investors actually ask, like “KVACW insider trading Form 4 transactions” or “Where is KVACW’s quarterly earnings report 10-Q filing?” Whether you need the latest 8-K detailing its Medera gene-therapy merger, a proxy statement on executive compensation, or a concise view of trust-account interest in the annual report, our real-time engine translates legal jargon into plain language.
- Instant alerts on KVACW Form 4 insider transactions real-time, including sponsor warrant sales
- AI-powered summaries of every 10-K and 10-Q—no scrolling required to see cash held in trust
- Side-by-side comparison of each amended proxy so you can spot new dilution terms fast
- Contextual explanations of 8-K material events, from LOI announcements to closing conditions
Keen Vision Acquisition (Nasdaq:KVAC) filed an 8-K after issuing a $200,000 unsecured, interest-free promissory note to its Sponsor on 23 Jun 2025. The cash was deposited into the SPAC trust, allowing the company to extend its business-combination deadline to 27 Jul 2025.
The note is convertible at the Sponsor’s option into units identical to the IPO units—one ordinary share and one warrant—at $10.00 per unit, and it matures upon completion of a business combination. Disclosures are made under Items 1.01 and 2.03; Exhibit 10.1 contains the full note.
- No interest expense will accrue, preserving cash.
- Creates an unsecured obligation until conversion or repayment.
- Extension reduces near-term liquidation risk but introduces potential dilution for public shareholders.
Keen Vision Acquisition Corporation ("KVAC") has filed a PRE 14A preliminary proxy statement to convene an Extraordinary General Meeting on 23 July 2025 in Hong Kong. Shareholders will vote on three key proposals that directly affect the special-purpose acquisition company’s (SPAC) life span and capital structure.
Proposal 1 – Trust Amendment: KVAC seeks authority to extend the deadline for commencing liquidation of its $72.6 million trust account up to six additional one-month periods, shifting the current cut-off from 27 July 2025 to 27 January 2026. Each monthly extension would require a deposit of $0.03 per remaining public share ("Extension Payment") instead of the existing flat $200,000 monthly fee. The change reduces the sponsor’s cash outlay when public share redemptions shrink the float and provides incremental optionality rather than a single long extension.
Proposal 2 – Charter Amendment: To give full legal effect to Proposal 1, shareholders must adopt a Third Amended & Restated Memorandum and Articles that formally sets the new outside date at 27 January 2026.
Proposal 3 – Adjournment: Allows the chair to adjourn the meeting if there are insufficient votes to pass Proposals 1 or 2, facilitating additional proxy solicitation.
Public shareholders may elect to redeem their ordinary shares for a pro-rata share of the trust regardless of how they vote. Redemption requests must reach Continental Stock Transfer & Trust at least two business days before the meeting via share certificate delivery or DWAC. If Proposals 1 & 2 fail and no business combination closes by the current deadline, the company will liquidate and redeem 100 % of Public Shares within ten business days.
The record date is 26 June 2025. The Trust Amendment requires approval by at least 50 % of all outstanding ordinary shares; the Charter Amendment and Adjournment proposals need a majority of shares present and voting. The Board unanimously recommends voting "FOR" all proposals, asserting that the lower, per-share extension cost aligns shareholder and sponsor interests while preserving the option to consummate a value-enhancing business combination.
FAQ
What is the current stock price of Keen Vision Acquisition (kvacw)?
What is Keen Vision Acquisition Corp (KVACW)?
What is the primary business model of KVACW?
How does KVACW add value as a blank check company?
What is the significance of the merger with Medera Inc.?
Which industry sectors does KVACW target?
What distinguishes KVACW from traditional operating companies?
How does KVACW sustain investor trust and transparency?
What role do industry-specific partnerships play for KVACW?
